Logos png-39.png

© Beta Bionics, 2020

Caution - THE iLet IS AN INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE

  • fb
  • tw
  • ig
  • in
  • yt

Press Releases

Beta Bionics, Inc. today announced that Martha G. Aronson and Sean D. Carney have been appointed to the Company’s Board of Directors effective immediately. “We are all very excited and feel extremely fortunate, at Beta Bionics, to have Martha and Sean join our Board of Directors. Their experience and expertise in the commercial and financial aspects of our business are substantial, and will be invaluable assets to our Board and management team going forward,” said Ed Damiano, President and CEO of Beta Bionics. 

Beta Bionics, Inc. announced it has received Breakthrough Device designation from the U.S. Food and Drug

Administration (FDA) for its investigational iLet Bionic Pancreas System.

July 17, 2019

ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world-class infusion sets available for use with the iLet Bionic Pancreas System.

January 08, 2019

Beta Bionics announces that the company has now completed its Series B equity financing, which has reached a total of $63 million.  

October 09, 2018

Beta Bionics has been awarded up to $2 million in the form of an SBIR grant (R44-DK120234) by the NIDDK, which is part of the U.S. National Institutes of Health (NIH).

Zealand Pharma and Beta Bionics announce a positive outcome from the Phase 2a clinical safety trial using dasiglucagon in the dual-hormone artificial pancreas system, developed at Boston University and licensed to Beta Bionics. 

Please reload